12:09 PM EDT, 04/28/2025 (MT Newswires) -- Castle Biosciences ( CSTL ) said Monday its DecisionDx-Melanoma clinical test for patients with cutaneous melanoma reached 200,000 orders.

The 31-gene expression profile test offers personalized results detailing a patient's predicted risk of recurrence or metastasis, the company said.

Shares were down 2.8% in recent trading.

Price: 20.05, Change: -0.58, Percent Change: -2.84